HIV drug rilpivirine keeps helping kids in Long-Term study
NCT ID NCT02494986
First seen Jun 26, 2026 · Last updated Jul 07, 2026 · Updated 3 times
Summary
This study gives children with HIV-1 who previously benefited from rilpivirine continued access to the drug along with other antiretrovirals. About 48 kids are taking part to monitor long-term safety and side effects. The goal is to keep their virus under control while checking for any problems over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rilpivirine (an antiretroviral drug)
- What this could lead to
- If successful, this study could confirm that rilpivirine is safe and effective for long-term use in children with HIV, helping them manage the virus.
- What could go wrong
- This is a small, open-label roll-over study (Phase 2) with no comparison group, so results may not apply broadly. Side effects like rash or serious adverse events are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Study site
Porto, Portugal
-
Study site
Bloemfontein, South Africa
-
Study site
Dundee, South Africa
-
Study site
Esplugues de Llobregat, Spain
-
Study site
Bangkok, Thailand
-
Study site
Nonthaburi, Thailand
-
Study site
Entebbe, Uganda
-
Study site
Kampala, Uganda
More trials for these conditions
Other studies related to the condition(s) this trial covers.